Targeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition

Qiang Jeremy Wen, Qiong Yang, Benjamin Goldenson, Sébastien Malinge, Terra Lasho, Rebekka K. Schneider, Lawrence J. Breyfogle, Rachael Schultz, Laure Gilles, Priya Koppikar, Omar Abdel-Wahab, Animesh D Pardanani, Brady Stein, Sandeep Gurbuxani, Ann Mullally, Ross L. Levine, Ayalew Tefferi, John D. Crispino

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Primary myelofibrosis (PMF) is characterized by bone marrow fibrosis, myeloproliferation, extramedullary hematopoiesis, splenomegaly and leukemic progression. Moreover, the bone marrow and spleens of individuals with PMF contain large numbers of atypical megakaryocytes that are postulated to contribute to fibrosis through the release of cytokines, including transforming growth factor (TGF)-β. Although the Janus kinase inhibitor ruxolitinib provides symptomatic relief, it does not reduce the mutant allele burden or substantially reverse fibrosis. Here we show through pharmacologic and genetic studies that aurora kinase A (AURKA) represents a new therapeutic target in PMF. Treatment with MLN8237, a selective AURKA inhibitor, promoted polyploidization and differentiation of megakaryocytes with PMF-associated mutations and had potent antifibrotic and antitumor activity in vivo in mouse models of PMF. Moreover, heterozygous deletion of Aurka was sufficient to ameliorate fibrosis and other PMF features in vivo. Our data suggest that megakaryocytes drive fibrosis in PMF and that targeting them with AURKA inhibitors has the potential to provide therapeutic benefit.

Original languageEnglish (US)
Pages (from-to)1473-1480
Number of pages8
JournalNature Medicine
Volume21
Issue number12
DOIs
StatePublished - Dec 1 2015

Fingerprint

Aurora Kinase A
Primary Myelofibrosis
Fibrosis
Bone
Janus Kinases
Megakaryocytes
Neoplasms
Transforming Growth Factors
Cytokines
Extramedullary Hematopoiesis
Splenomegaly
Spleen
Bone Marrow
Alleles
Mutation

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Jeremy Wen, Q., Yang, Q., Goldenson, B., Malinge, S., Lasho, T., Schneider, R. K., ... Crispino, J. D. (2015). Targeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition. Nature Medicine, 21(12), 1473-1480. https://doi.org/10.1038/nm.3995

Targeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition. / Jeremy Wen, Qiang; Yang, Qiong; Goldenson, Benjamin; Malinge, Sébastien; Lasho, Terra; Schneider, Rebekka K.; Breyfogle, Lawrence J.; Schultz, Rachael; Gilles, Laure; Koppikar, Priya; Abdel-Wahab, Omar; Pardanani, Animesh D; Stein, Brady; Gurbuxani, Sandeep; Mullally, Ann; Levine, Ross L.; Tefferi, Ayalew; Crispino, John D.

In: Nature Medicine, Vol. 21, No. 12, 01.12.2015, p. 1473-1480.

Research output: Contribution to journalArticle

Jeremy Wen, Q, Yang, Q, Goldenson, B, Malinge, S, Lasho, T, Schneider, RK, Breyfogle, LJ, Schultz, R, Gilles, L, Koppikar, P, Abdel-Wahab, O, Pardanani, AD, Stein, B, Gurbuxani, S, Mullally, A, Levine, RL, Tefferi, A & Crispino, JD 2015, 'Targeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition', Nature Medicine, vol. 21, no. 12, pp. 1473-1480. https://doi.org/10.1038/nm.3995
Jeremy Wen Q, Yang Q, Goldenson B, Malinge S, Lasho T, Schneider RK et al. Targeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition. Nature Medicine. 2015 Dec 1;21(12):1473-1480. https://doi.org/10.1038/nm.3995
Jeremy Wen, Qiang ; Yang, Qiong ; Goldenson, Benjamin ; Malinge, Sébastien ; Lasho, Terra ; Schneider, Rebekka K. ; Breyfogle, Lawrence J. ; Schultz, Rachael ; Gilles, Laure ; Koppikar, Priya ; Abdel-Wahab, Omar ; Pardanani, Animesh D ; Stein, Brady ; Gurbuxani, Sandeep ; Mullally, Ann ; Levine, Ross L. ; Tefferi, Ayalew ; Crispino, John D. / Targeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition. In: Nature Medicine. 2015 ; Vol. 21, No. 12. pp. 1473-1480.
@article{53c52c3a5d6447608111391715da7ec9,
title = "Targeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition",
abstract = "Primary myelofibrosis (PMF) is characterized by bone marrow fibrosis, myeloproliferation, extramedullary hematopoiesis, splenomegaly and leukemic progression. Moreover, the bone marrow and spleens of individuals with PMF contain large numbers of atypical megakaryocytes that are postulated to contribute to fibrosis through the release of cytokines, including transforming growth factor (TGF)-β. Although the Janus kinase inhibitor ruxolitinib provides symptomatic relief, it does not reduce the mutant allele burden or substantially reverse fibrosis. Here we show through pharmacologic and genetic studies that aurora kinase A (AURKA) represents a new therapeutic target in PMF. Treatment with MLN8237, a selective AURKA inhibitor, promoted polyploidization and differentiation of megakaryocytes with PMF-associated mutations and had potent antifibrotic and antitumor activity in vivo in mouse models of PMF. Moreover, heterozygous deletion of Aurka was sufficient to ameliorate fibrosis and other PMF features in vivo. Our data suggest that megakaryocytes drive fibrosis in PMF and that targeting them with AURKA inhibitors has the potential to provide therapeutic benefit.",
author = "{Jeremy Wen}, Qiang and Qiong Yang and Benjamin Goldenson and S{\'e}bastien Malinge and Terra Lasho and Schneider, {Rebekka K.} and Breyfogle, {Lawrence J.} and Rachael Schultz and Laure Gilles and Priya Koppikar and Omar Abdel-Wahab and Pardanani, {Animesh D} and Brady Stein and Sandeep Gurbuxani and Ann Mullally and Levine, {Ross L.} and Ayalew Tefferi and Crispino, {John D.}",
year = "2015",
month = "12",
day = "1",
doi = "10.1038/nm.3995",
language = "English (US)",
volume = "21",
pages = "1473--1480",
journal = "Nature Medicine",
issn = "1078-8956",
publisher = "Nature Publishing Group",
number = "12",

}

TY - JOUR

T1 - Targeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition

AU - Jeremy Wen, Qiang

AU - Yang, Qiong

AU - Goldenson, Benjamin

AU - Malinge, Sébastien

AU - Lasho, Terra

AU - Schneider, Rebekka K.

AU - Breyfogle, Lawrence J.

AU - Schultz, Rachael

AU - Gilles, Laure

AU - Koppikar, Priya

AU - Abdel-Wahab, Omar

AU - Pardanani, Animesh D

AU - Stein, Brady

AU - Gurbuxani, Sandeep

AU - Mullally, Ann

AU - Levine, Ross L.

AU - Tefferi, Ayalew

AU - Crispino, John D.

PY - 2015/12/1

Y1 - 2015/12/1

N2 - Primary myelofibrosis (PMF) is characterized by bone marrow fibrosis, myeloproliferation, extramedullary hematopoiesis, splenomegaly and leukemic progression. Moreover, the bone marrow and spleens of individuals with PMF contain large numbers of atypical megakaryocytes that are postulated to contribute to fibrosis through the release of cytokines, including transforming growth factor (TGF)-β. Although the Janus kinase inhibitor ruxolitinib provides symptomatic relief, it does not reduce the mutant allele burden or substantially reverse fibrosis. Here we show through pharmacologic and genetic studies that aurora kinase A (AURKA) represents a new therapeutic target in PMF. Treatment with MLN8237, a selective AURKA inhibitor, promoted polyploidization and differentiation of megakaryocytes with PMF-associated mutations and had potent antifibrotic and antitumor activity in vivo in mouse models of PMF. Moreover, heterozygous deletion of Aurka was sufficient to ameliorate fibrosis and other PMF features in vivo. Our data suggest that megakaryocytes drive fibrosis in PMF and that targeting them with AURKA inhibitors has the potential to provide therapeutic benefit.

AB - Primary myelofibrosis (PMF) is characterized by bone marrow fibrosis, myeloproliferation, extramedullary hematopoiesis, splenomegaly and leukemic progression. Moreover, the bone marrow and spleens of individuals with PMF contain large numbers of atypical megakaryocytes that are postulated to contribute to fibrosis through the release of cytokines, including transforming growth factor (TGF)-β. Although the Janus kinase inhibitor ruxolitinib provides symptomatic relief, it does not reduce the mutant allele burden or substantially reverse fibrosis. Here we show through pharmacologic and genetic studies that aurora kinase A (AURKA) represents a new therapeutic target in PMF. Treatment with MLN8237, a selective AURKA inhibitor, promoted polyploidization and differentiation of megakaryocytes with PMF-associated mutations and had potent antifibrotic and antitumor activity in vivo in mouse models of PMF. Moreover, heterozygous deletion of Aurka was sufficient to ameliorate fibrosis and other PMF features in vivo. Our data suggest that megakaryocytes drive fibrosis in PMF and that targeting them with AURKA inhibitors has the potential to provide therapeutic benefit.

UR - http://www.scopus.com/inward/record.url?scp=84949623272&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84949623272&partnerID=8YFLogxK

U2 - 10.1038/nm.3995

DO - 10.1038/nm.3995

M3 - Article

C2 - 26569382

AN - SCOPUS:84949623272

VL - 21

SP - 1473

EP - 1480

JO - Nature Medicine

JF - Nature Medicine

SN - 1078-8956

IS - 12

ER -